Abstract
Panitumumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, prolongs progression-free survival in patients with metastatic colorectal cancer and wild-type KRAS tumours when administered intravenously in combination with FOLFOX as first-line treatment, in combination with FOLFIRI as second-line treatment, or as monotherapy in chemotherapy-refractory disease. It has an acceptable tolerability profile, is associated with the skinrelated toxicities characteristic of EGFR inhibitors and appears to have a low risk of immunogenicity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
